Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 4/20 | 0.36 |
| ▸ | LCK | P06239 | 2/20 | 0.35 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31590994 | 0.89 | MAPT (0.45) | RORC | |
| SCHEMBL30469723 | 0.88 | PTPN11 (0.43) | CA12CA1CA9RORCLCK | |
| SCHEMBL24364158 | 0.88 | PTPN11 (0.43) | CA12CA1CA9RORCLCK | |
| SCHEMBL29346060 | 0.88 | CA12 (0.38) | CA12CA1CA9ATRRORC | |
| SCHEMBL29081978 | 0.87 | MAPKAPK2 (0.37) | CA12CA1CA9RORCLCK | |
| SCHEMBL29477860 | 0.87 | MAPKAPK2 (0.37) | CA12CA1CA9RORCLCK | |
| SCHEMBL30469640 | 0.85 | AR (0.37) | RORCLCKMAPKAPK2SYK | |
| SCHEMBL24364159 | 0.85 | AR (0.37) | RORCLCKMAPKAPK2SYK | |
| SCHEMBL24365623 | 0.82 | DGAT1 (0.46) | ATRRORCMAPKAPK2SYKDGAT1 | |
| SCHEMBL7416577 | 0.79 | LCK (0.45) | CA12CA1CA9ATRRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | CA12 1198/4885CA1 1719/4885CA9 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.